A detailed history of Russell Investments Group, Ltd. transactions in Nektar Therapeutics stock. As of the latest transaction made, Russell Investments Group, Ltd. holds 89,441 shares of NKTR stock, worth $91,229. This represents 0.0% of its overall portfolio holdings.

Number of Shares
89,441
Previous 89,698 0.29%
Holding current value
$91,229
Previous $111,000 4.5%
% of portfolio
0.0%
Previous 0.0%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$1.11 - $1.48 $285 - $380
-257 Reduced 0.29%
89,441 $116,000
Q2 2024

Aug 08, 2024

BUY
$0.9 - $1.83 $6,537 - $13,293
7,264 Added 8.81%
89,698 $111,000
Q1 2024

May 08, 2024

SELL
$0.49 - $0.96 $14,864 - $29,121
-30,335 Reduced 26.9%
82,434 $76,000
Q4 2023

Feb 05, 2024

SELL
$0.42 - $0.57 $19,282 - $26,169
-45,911 Reduced 28.93%
112,769 $63,000
Q3 2023

Nov 13, 2023

SELL
$0.51 - $1.05 $883 - $1,819
-1,733 Reduced 1.08%
158,680 $95,000
Q1 2023

May 09, 2023

SELL
$0.64 - $3.15 $1,713 - $8,435
-2,678 Reduced 1.64%
160,413 $112,000
Q4 2022

Feb 08, 2023

BUY
$2.03 - $4.28 $162,420 - $342,442
80,010 Added 96.3%
163,091 $368,000
Q3 2022

Nov 04, 2022

BUY
$3.04 - $5.14 $241,999 - $409,169
79,605 Added 2290.13%
83,081 $264,000
Q2 2022

Jul 29, 2022

SELL
$3.17 - $6.17 $27,699 - $53,913
-8,738 Reduced 71.54%
3,476 $13,000
Q1 2022

May 05, 2022

SELL
$4.16 - $13.72 $8,810 - $29,058
-2,118 Reduced 14.78%
12,214 $64,000
Q4 2021

Jan 21, 2022

SELL
$10.83 - $18.41 $52,027 - $88,441
-4,804 Reduced 25.1%
14,332 $193,000
Q3 2021

Nov 08, 2021

SELL
$13.07 - $18.84 $18,010 - $25,961
-1,378 Reduced 6.72%
19,136 $343,000
Q2 2021

Aug 04, 2021

SELL
$16.52 - $20.4 $168,751 - $208,386
-10,215 Reduced 33.24%
20,514 $351,000
Q1 2021

May 10, 2021

SELL
$16.56 - $25.46 $229,885 - $353,435
-13,882 Reduced 31.12%
30,729 $613,000
Q4 2020

Feb 08, 2021

SELL
$15.77 - $19.03 $19,633 - $23,692
-1,245 Reduced 2.72%
44,611 $762,000
Q3 2020

Nov 09, 2020

SELL
$16.59 - $24.79 $79,947 - $119,463
-4,819 Reduced 9.51%
45,856 $759,000
Q2 2020

Aug 05, 2020

BUY
$16.86 - $23.44 $836,171 - $1.16 Million
49,595 Added 4592.13%
50,675 $1.17 Million
Q1 2020

May 06, 2020

BUY
$14.47 - $27.96 $11,026 - $21,305
762 Added 239.62%
1,080 $19,000
Q4 2019

Jan 29, 2020

SELL
$15.87 - $23.12 $56,735 - $82,654
-3,575 Reduced 91.83%
318 $6,000
Q1 2019

May 13, 2019

BUY
$31.58 - $46.35 $10,042 - $14,739
318 Added 8.9%
3,893 $128,000
Q4 2018

Feb 11, 2019

SELL
$30.43 - $56.65 $43,910 - $81,745
-1,443 Reduced 28.76%
3,575 $120,000
Q3 2018

Oct 26, 2018

SELL
$46.46 - $68.49 $1.99 Million - $2.94 Million
-42,916 Reduced 89.53%
5,018 $305,000
Q2 2018

Aug 08, 2018

SELL
$46.25 - $104.45 $948,818 - $2.14 Million
-20,515 Reduced 29.97%
47,934 $2.34 Million
Q1 2018

May 11, 2018

SELL
$57.4 - $108.44 $2.64 Million - $4.98 Million
-45,967 Reduced 40.18%
68,449 $7.26 Million
Q4 2017

Feb 06, 2018

SELL
$23.02 - $60.5 $288,785 - $758,972
-12,545 Reduced 9.88%
114,416 $6.92 Million
Q3 2017

Nov 07, 2017

BUY
$17.79 - $24.0 $2.26 Million - $3.05 Million
126,961
126,961 $3.05 Million

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $191M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Russell Investments Group, Ltd. Portfolio

Follow Russell Investments Group, Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Russell Investments Group, Ltd. with notifications on news.